← Back to Search

Everolimus for Tumors

N/A
Waitlist Available
Research Sponsored by Sinai Hospital of Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 10 Other Conditions
All Individual Drugs Already Approved

Summary

The purpose of this research study is to understand if platelets in the blood become more active during cancer and specially advanced stages of cancer, in the future the investigators want to see if reducing platelet activity can improve survival in advanced cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: CasesActive Control1 Intervention
Patients with cancer whose platelets are examined
Group II: ControlPlacebo Group2 Interventions
Patients without cancer whose platelets are examined for comparison

Find a Location

Who is running the clinical trial?

Sinai Hospital of BaltimoreLead Sponsor
7 Previous Clinical Trials
358 Total Patients Enrolled
~4 spots leftby Nov 2025